Beyond Solubility Enhancement: Multiobjective Formulation Design for Bioavailability, Stability, Manufacturability, Safety, and Patient Acceptability across Development Stages

Pharmaceutical formulation development is frequently organized around a dominant technical obstacle, with poor aqueous solubility often treated as the principal variable to be corrected. Although solubility enhancement may improve dissolution or create favorable exposure hypotheses, it does not by itself establish dosage-form viability, because the resulting formulation may remain unstable, difficult to manufacture, unsafe for the intended population, or unacceptable in actual use. This article develops an original, non-empirical Multiobjective Formulation Design Framework that treats biopharmaceutical performance, physical, chemical, and microbiological stability, manufacturability and control, excipient and product safety, and patient acceptability as coupled design domains. The framework separates optimizable objectives from non-compensatory constraints and organizes formulation decisions through candidate and process variables, an objective vector, a hard-constraint gate, explicit characterization of evidence and uncertainty, an evidence-adjusted feasible design space, a stage-conditioned Pareto set, and a traceable governance record. Excipient safety and patient acceptability are positioned as design-defining considerations rather than downstream checks. Trade-off analysis is used to identify defensible compromise candidates without implying that any formulation is universally optimal. Stage-specific evidence requirements determine which claims may be supported during discovery, preformulation, process development, clinical translation, and lifecycle management. The original contribution is the integration of previously separated formulation domains into a reversible decision architecture in which candidate status depends on evidence relevance, uncertainty, development stage, and context of use. Computational predictions, laboratory measurements, manufacturing studies, stability-indicating methods, population-specific acceptability assessments, and clinically relevant performance evidence remain necessary for validation. The framework does not establish product-specific superiority, clinical benefit, regulatory acceptability, or deployment readiness.